3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Glioblastoma
154
Brain Neoplasms
73
Glioma
69
Central Nervous System Neoplasms
50
Gliosarcoma
46
Astrocytoma
37
Melanoma
36
Oligodendroglioma
29
Neuroblastoma
17
Neoplasm Metastasis
14
Carcinoma, Non-Small-Cell Lung
12
Lung Neoplasms
11
Sarcoma, Ewing
10
Sarcoma
10
Neoplasms
10
Medulloblastoma
10
Recurrence
9
Neuroendocrine Tumors
9
Lymphoma
8
Ependymoma
8
Breast Neoplasms
8
Small Cell Lung Carcinoma
7
Rhabdomyosarcoma
7
Diffuse Intrinsic Pontine Glioma
7
Colorectal Neoplasms
7
Carcinoma, Neuroendocrine
6
Adenoma, Islet Cell
6
Uveal Melanoma
5
Spinal Cord Neoplasms
5
Pheochromocytoma
5
Interventions
Leucovorin
2
Irinotecan
2
Fluorouracil
2
dostarlimab
1
avelumab
1
Varenicline
1
Tobacco Use Cessation Devices
1
Temozolomide
1
Radiotherapy
1
Panitumumab
1
Nicotine Chewing Gum
1
Cetuximab
1
Bupropion
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Second Primary
×
Temozolomide
×
Clear all
NCT00638963
2017-06-14
STOP
Merck Sharp & Dohme LLC
Phase 2
Terminated
6 enrolled
9 charts